- Home
- FT vs STTK Comparison
FT vs STTK Comparison
Compare FT & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FT
- STTK
- Stock Information
- Founded
- FT 1988
- STTK 2016
- Country
- FT United States
- STTK United States
- Employees
- FT N/A
- STTK N/A
- Industry
- FT Trusts Except Educational Religious and Charitable
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- FT Finance
- STTK Health Care
- Exchange
- FT Nasdaq
- STTK Nasdaq
- Market Cap
- FT 171.4M
- STTK 173.6M
- IPO Year
- FT N/A
- STTK 2020
- Fundamental
- Price
- FT $7.52
- STTK $3.76
- Analyst Decision
- FT
- STTK Strong Buy
- Analyst Count
- FT 0
- STTK 3
- Target Price
- FT N/A
- STTK $10.67
- AVG Volume (30 Days)
- FT 63.0K
- STTK 123.5K
- Earning Date
- FT 01-01-0001
- STTK 11-07-2024
- Dividend Yield
- FT 7.85%
- STTK N/A
- EPS Growth
- FT N/A
- STTK N/A
- EPS
- FT N/A
- STTK N/A
- Revenue
- FT N/A
- STTK $4,123,999.00
- Revenue This Year
- FT N/A
- STTK $164.45
- Revenue Next Year
- FT N/A
- STTK N/A
- P/E Ratio
- FT N/A
- STTK N/A
- Revenue Growth
- FT N/A
- STTK 380.09
- 52 Week Low
- FT $5.97
- STTK $1.33
- 52 Week High
- FT $7.23
- STTK $11.76
- Technical
- Relative Strength Index (RSI)
- FT 79.01
- STTK 53.48
- Support Level
- FT $7.31
- STTK $3.63
- Resistance Level
- FT $7.33
- STTK $3.94
- Average True Range (ATR)
- FT 0.06
- STTK 0.23
- MACD
- FT 0.01
- STTK 0.05
- Stochastic Oscillator
- FT 96.97
- STTK 68.42
About FT Franklin Universal Trust
Franklin Universal Trust is a closed-end management investment company. Its primary investment objective is to provide high, current income consistent with the preservation of capital. Its secondary objective is the growth of income through dividend increases and capital appreciation. The fund invests in two asset classes being the high yield bonds and utility stocks.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.